Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma

Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Xuejiao Chen; Dawei Rong; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang

doi:10.1155/2021/3002480

Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma

J Oncol. 2021 Dec 10:2021:3002480. doi: 10.1155/2021/3002480. eCollection 2021.

Authors

Xiaoyuan Chen^{1

2

3

4}, Yiwei Lu^{2

3

4}, Xiaoli Shi^{1

2

3

4}, Xuejiao Chen^{2

3

4}, Dawei Rong^{1

2

3

4}, Guoyong Han^{2

3

4}, Long Zhang^{2

3

4}, Chuangye Ni^{2

3

4}, Jie Zhao^{2

3

4

5}, Yun Gao^{2

3

4}, Xuehao Wang^{1

2

3

4}

Affiliations

¹ School of Medicine, Southeast University, Nanjing, China.
² Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
³ Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, China.
⁴ NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, China.
⁵ Department of General Surgery, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Background: Combined hepatocellular-cholangiocarcinoma (CHC) is a rare and heterogeneous histological subtype of primary liver cancer, which is still poorly understood. This study aimed to describe the epidemiological and clinical features, investigate the prognostic indicators, and develop a competing risk nomogram for CHC.

Methods: The study cohort was taken from the Surveillance, Epidemiology, and End Results database. The annual percent change (APC) in incidence was calculated using the joinpoint regression. The nomogram was developed based on multivariate competing risk survival analyses and validated by calibration curves. Akaike information criterion, Bayesian information criterion, Harrell's C-index, and area under the receiver operating characteristic curves were obtained to compare prognostic performance. Decision curve analysis was introduced to examine the clinical value of the models.

Results: The overall incidence of CHC was 0.062 per 100,000 individuals in 2004 and 0.081 per 100,000 individuals in 2018, with an APC of 1.0% (P > 0.05). CHC displayed intermediate clinicopathological features of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Race, tumor size, vascular invasion, extrahepatic invasion, distant metastasis, grade, surgery, and Metavir stage were confirmed as the independent predictors of cancer-specific survival. The constructed nomogram was well calibrated, which showed better discrimination power and higher net benefits than the current American Joint Committee on Cancer staging system. Patients with liver transplantation had better survival than those with hepatectomy, especially patients within the Milan Criteria (P=0.022 and P=0.015). There was no survival difference between liver transplantation and hepatectomy in patients beyond the Milan Criteria (P=0.340).

Conclusion: The morbidity of CHC remained stable between 2004 and 2018. The constructed nomogram could predict the prognosis with good performance, which was meaningful to individual treatment strategies optimization. CHC patients should also be considered as potential liver transplantation recipients, especially those within the Milan Criteria, but the finding still needs more evidence to be further confirmed.